Wegovy Cost Without Insurance 2026

See if you qualify in 5 minutes →
5-minute questionnaire · reviewed by a licensed clinician · The Nouri Promise: a full refund if you’re not satisfied in your first 30 days, available on 3-month and 6-month plans · cancel anytime

Wegovy cost without insurance: at a glance

Prices reflect publicly available information as of June 2026 and change frequently. Verify all figures with the manufacturer, your pharmacy, and your insurer before deciding. For a broader comparison across all GLP-1 programs, see the complete 2026 GLP-1 cost guide.

What Wegovy actually costs without insurance

The ~$1,349 list price is the wholesale acquisition cost — a sticker number that most patients never pay. The figure that matters for self-pay patients is the NovoCare self-pay price: about $349/month for the injectable pen (as of June 2026, per Novo Nordisk’s NovoCare program).

Novo also introduced an oral version — the Wegovy pill — which carries a lower self-pay price of about $149/month. If the daily-pill routine works for you, this is currently the lowest-cost FDA-approved semaglutide option at self-pay.

Why is the list price so high? Brand-name GLP-1 medications carry significant R&D and patent costs, and no biosimilar or generic has reached the U.S. market yet. Until competition arrives — analysts project semaglutide biosimilars in the late 2020s — the list price will remain largely a reference number for insurance negotiations.

How NovoCare self-pay pricing works

NovoCare is Novo Nordisk’s patient-support program. At self-pay (meaning: you have no insurance, or your insurance does not cover Wegovy, or you choose not to use insurance), NovoCare sets the price directly with the patient rather than billing through a plan.

As of June 2026, the self-pay injectable pen is about $349/month. Novo has offered an introductory rate of approximately $199/month for the first two fills for eligible self-pay patients — but introductory terms change; verify the current offer before you begin treatment. To access NovoCare pricing, patients typically fill through a participating pharmacy and use the NovoCare program materials from their prescriber.

NovoCare self-pay pricing is not the same as an insurance savings card. Savings cards require an active commercial insurance plan that covers the drug; self-pay pricing is for patients paying out of pocket with no insurance billing.

The Wegovy pill: a lower-cost self-pay option

In December 2025, the FDA approved an oral semaglutide tablet (25 mg) under the Wegovy brand for chronic weight management. At self-pay, this is priced at about $149/month — meaningfully less than the injectable pen at ~$349.

The trade-offs: the pill must be taken once daily on an empty stomach, with no food or drink for 30 minutes after taking it, and with a full glass of plain water only. Absorption can be significantly reduced by food, other beverages, or other medications taken at the same time. For people who prefer not to self-inject once weekly, the pill is a compelling alternative on cost; for people who find the administration requirements easy to miss, the once-weekly injection may be more reliable in practice.

Both the injectable pen and the pill are FDA-approved brand-name Wegovy products containing semaglutide, made by Novo Nordisk. Neither is a compounded product.

Wegovy cost with insurance

If your commercial insurance plan covers Wegovy, Novo Nordisk offers a savings card that can reduce your copay to as little as $25/month. That figure comes with important conditions: the drug must be on your plan’s formulary, your plan must not exclude weight-loss drugs, and you must not be on Medicare or Medicaid (savings cards do not apply to federal programs).

Coverage is the central obstacle. Studies of employer health plans have found that roughly 40% exclude weight-loss drugs entirely. Many that do cover them require prior authorization, documenting a BMI of 30 or higher (or 27+ with a weight-related comorbidity), and often require documentation that the patient has tried other weight-management strategies first. Getting that authorization approved can take weeks and may require your prescriber to submit supporting records.

Medicare coverage for Wegovy

Traditional Medicare Part D historically excluded weight-loss drugs under a statutory carve-out. Starting July 1, 2026, the CMS Medicare GLP-1 Bridge Program is set to allow Medicare beneficiaries to access certain GLP-1 medications at approximately $50/month. Verify the current drug list and eligibility rules on the CMS newsroom page, as details may change before and after the launch date.

Medicaid coverage for Wegovy

Medicaid coverage for GLP-1 weight-loss medications varies by state. As of mid-2026, a minority of state Medicaid programs cover Wegovy or similar medications for weight management — and where they do, requirements differ substantially. Check your state’s Medicaid formulary directly. Manufacturer savings cards (including Novo’s) do not apply to Medicaid.

Why Wegovy costs more than Ozempic — and when that matters

Wegovy and Ozempic are both brand-name semaglutide products made by Novo Nordisk, but they are different products with different FDA-approved indications and dosing schedules. Wegovy is FDA-approved for chronic weight management; Ozempic is FDA-approved for type 2 diabetes management and cardiovascular risk reduction.

The dosing is different: Wegovy goes up to 2.4 mg once weekly, while Ozempic’s approved doses top out at 1 mg or 2 mg weekly for diabetes. The list prices reflect this: Wegovy’s list is about $1,349/month versus Ozempic’s ~$997/month (as of June 2026). At NovoCare self-pay, both products currently land near $349/month.

For a detailed breakdown of both products on cost and coverage, see the semaglutide cost guide, which covers Wegovy, Ozempic, and Rybelsus side by side.

Is there a generic version of Wegovy?

No. Novo Nordisk holds multiple patents on semaglutide — including the molecule, the injection device, and the formulation — that analysts project will not begin to expire until approximately 2032. No FDA-approved generic semaglutide product is available in the United States as of mid-2026.

The closest lower-cost alternative is compounded semaglutide — patient-specific preparations made by state-licensed 503A compounding pharmacies. These are not FDA-approved, not the same as Wegovy, and not therapeutically equivalent to any FDA-approved drug. Compounded semaglutide can only be obtained with a valid prescription from a licensed provider. See the dedicated section below for details on how compounding fits into the cost picture.

How Wegovy compares to Zepbound on cost

Zepbound (tirzepatide, by Eli Lilly) is the other major FDA-approved injectable for weight management. At self-pay, Lilly sells Zepbound through its LillyDirect program at $299–$449/month depending on dose, as of June 2026. That puts it in a similar range to Wegovy’s ~$349/month NovoCare self-pay price; the comparison depends on which dose your prescriber recommends.

These are different drugs. Wegovy contains semaglutide (a GLP-1 receptor agonist); Zepbound contains tirzepatide (a dual GIP/GLP-1 receptor agonist). They work through related but distinct mechanisms and are not interchangeable. In published clinical trials of the FDA-approved branded drugs — STEP-1 for semaglutide (Wilding et al., NEJM 2021) and SURMOUNT-1 for tirzepatide (Jastreboff et al., NEJM 2022) — tirzepatide showed greater average weight loss than semaglutide. Individual results vary; these are trials of the branded drugs, not of any compounded product. Which medication is appropriate for a given patient is a clinical decision made by a licensed provider.

For a full cost-side breakdown of Zepbound at each tier, see Zepbound cost without insurance.

Compounded semaglutide: a non-FDA-approved lower-cost path

What it is. Compounded semaglutide is a patient-specific medication prepared by a state-licensed 503A compounding pharmacy. It is not manufactured by Novo Nordisk and is not FDA-approved. The FDA’s guidance on human drug compounding makes clear that compounded drugs do not undergo the same safety, efficacy, and manufacturing review as FDA-approved drugs. Compounded semaglutide is not the same as, and is not therapeutically equivalent to, Wegovy or any other FDA-approved semaglutide product.

How it is prescribed. A licensed provider evaluates the patient and, when clinically appropriate, issues a prescription. The prescription is filled by a state-licensed 503A pharmacy. Not every patient is a candidate; prescribers make that determination. The NIDDK overview of prescription weight-management medications provides context on how providers evaluate these options.

What it costs. Telehealth programs offering compounded semaglutide vary widely in their pricing and what is included. Market prices run roughly $99–$199/month, though what is bundled into that figure varies. Watch for “$99/month” teaser pricing that adds a separate $49–$79/month membership on top; compare all-in costs. Nouri publishes its pricing openly — including in the Nouri GLP-1 telehealth pricing dataset on HuggingFace — so patients can compare apples to apples.

Regulatory context. The FDA has raised concerns about compounded GLP-1 products, including issues with labeling, dosing, and unauthorized versions of the drugs. Patients considering compounded semaglutide should use only licensed prescribers and state-licensed 503A compounding pharmacies, not grey-market or unapproved suppliers. See the FDA’s postmarket safety information page for current guidance.

Where Nouri fits on cost

Nouri offers compounded semaglutide and compounded tirzepatide as part of a comprehensive program. Pricing (as of June 2026):

• Compounded semaglutide: $120/month on the 6-month plan ($720 billed every 6 months); $145/month on the 3-month plan ($435 every 3 months); $175/month billed monthly.
• Compounded tirzepatide: $175/month on the 6-month plan ($1,050 every 6 months); $199/month on the 3-month plan ($597 every 3 months); $225/month billed monthly.

These are all-in prices. The program includes the compounded GLP-1 medication (when prescribed), a personalized nutrition plan, a movement and fitness plan, and ongoing care from the Nouri Care Team. Any dose, same price. Available in all 50 U.S. states. Medication is dispensed through Jungle Jim’s Pharmacy (a state-licensed 503A pharmacy in Fairfield, OH) and VialsRX. Nouri is LegitScript-certified.

The “$99/month” headline prices you see from some competitors add a separate membership fee on top; compare the all-in number, not just the medication line item, when evaluating options.

The Nouri Promise: if you’re not satisfied in your first 30 days, you get a full refund — available on 3-month and 6-month plans.

Important: Nouri’s compounded medications are not FDA-approved and are not the same as, or therapeutically equivalent to, Wegovy, Ozempic, Zepbound, or Mounjaro. Medication is prescribed only if clinically appropriate, after review by a licensed provider. Not all applicants qualify.

Start your 5-minute assessment →
5-minute questionnaire · reviewed by a licensed clinician · cancel anytime

Related cost guides

• Full 2026 GLP-1 cost guide (all programs compared) — pricing pillar
• Zepbound cost without insurance
• Does insurance cover Wegovy & Zepbound?
• Semaglutide cost with & without insurance
• Compounded vs. brand GLP-1 cost comparison
• Cheapest way to get a GLP-1 (full comparison)
• How to get a GLP-1 covered by insurance

Frequently asked questions

How much is Wegovy without insurance per month?

As of June 2026, Wegovy’s list price is about $1,349/month, but Novo’s NovoCare self-pay program offers the injectable pen at about $349/month (with an introductory ~$199/month for the first two fills — verify current terms on Wegovy.com, as this offer had a ~June 30, 2026 expiry). The Wegovy pill (oral semaglutide) is about $149/month at self-pay.

Why is Wegovy more expensive than Ozempic?

Both are brand-name semaglutide products made by Novo Nordisk, but Wegovy is approved for weight management at higher weekly doses (up to 2.4 mg) versus Ozempic’s diabetes indication (up to 2 mg), and Wegovy carries a higher list price (~$1,349/month versus ~$997 for Ozempic as of June 2026). At NovoCare self-pay, both products currently land near $349/month.

How much is Wegovy with insurance?

If your commercial plan covers Wegovy for weight management, a Novo savings card can bring the copay to as little as $25/month. However, roughly 40% of employer plans exclude weight-loss medications, most require prior authorization, and manufacturer savings cards do not apply to Medicare or Medicaid. Check your plan’s formulary before assuming coverage. For a full walkthrough, see does insurance cover Wegovy & Zepbound?

How do I get Wegovy for $199 a month?

Novo’s NovoCare self-pay program has offered an introductory ~$199/month price for the first two fills of the Wegovy pen for eligible self-pay patients. Introductory pricing has expiration dates — verify the current terms directly on Wegovy.com before assuming it is still available. After the introductory period, NovoCare self-pay is about $349/month.

Is the Wegovy pill cheaper than the injection?

At self-pay, yes — the Wegovy pill (oral semaglutide 25 mg, FDA-approved December 2025) is about $149/month versus ~$349 for the injectable pen. The pill must be taken daily on an empty stomach with strict timing; the injection is taken once weekly. Both are FDA-approved brand-name products containing semaglutide.

Is Zepbound cheaper than Wegovy?

At self-pay the prices are close: Zepbound vials run about $299–$449/month through LillyDirect (depending on dose, as of June 2026) versus Wegovy at ~$349/month. Zepbound contains tirzepatide and Wegovy contains semaglutide — these are different molecules with different mechanisms and are not interchangeable. In published clinical trials of the branded drugs, tirzepatide showed greater average weight loss than semaglutide; individual results vary, and those trials are of the FDA-approved branded products.

Is compounded semaglutide the same as Wegovy?

No. Compounded semaglutide is a patient-specific medication prepared by a state-licensed 503A compounding pharmacy. It is not FDA-approved and is not the same as, or therapeutically equivalent to, Wegovy or any other FDA-approved semaglutide product. It can only be obtained with a valid prescription from a licensed provider, who determines whether it is clinically appropriate for the individual patient. The FDA has issued guidance on compounded GLP-1 medications — see FDA.gov on human drug compounding for current information.

Sources & references

1. Wegovy.com — NovoCare self-pay and savings options (Novo Nordisk; verified June 2026)
2. LillyDirect — Zepbound self-pay vials (Eli Lilly; verified June 2026)
3. CMS — Medicare GLP-1 Bridge Program ($50/month, July 2026)
4. FDA — Human drug compounding overview
5. FDA — Postmarket drug safety information (GLP-1 compounding concerns)
6. NIDDK / NIH — Prescription medications to treat overweight and obesity
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). NEJM 2021.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022.
9. GoodRx — GLP-1 drug cost and savings overview
10. Nouri program pricing and telehealth pricing dataset — GLP-1 telehealth pricing dataset, HuggingFace (June 2026); joinnouri.com/becoming.

Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as pricing and guidance change. Last reviewed June 2026.

Prices and coverage described here are accurate as of June 2026 and change frequently — verify current figures with the manufacturer, your pharmacy, your insurer, and (for HSA/FSA or tax questions) a tax professional before making decisions. This is general information, not medical, financial, or tax advice. Individual results vary. Ozempic®, Wegovy®, and Rybelsus® are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company; Nouri is not affiliated with, endorsed by, or sponsored by these companies. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs. Compounded medications are prescribed only when a licensed provider determines they are clinically appropriate for the individual patient.